WFIKKN2

4 papers study it1 finding

HGNC NCBI Gene Taxon

1 lab in 1 country

Human trial2
Humans2

Interventions

1

Liraglutide

upin humans1

1 study

Liraglutide increases WFIKKN2 in humans.
“its inhibitor WFIKKN2, alongside TGF-β receptor BMPR1a were upregulated”
Human trial3.0 mg/day5 weeks
OR09-07 Dynamic Proteomic Profiling in a 5-week Crossover Trial of Liraglutide in Obesity Reveals Weight-Dependent Myostatin Downregulation and Multi-Pathway Effects Beyond Weight Reduction
ENDO 2025 abstractOct 22, 2025

More on Liraglutide

Latest

ENDO 2025 AbstractOct 23

OR09-07 Dynamic Proteomic Profiling in a 5-week Crossover Trial of Liraglutide in Obesity Reveals Weight-Dependent Myostatin Downregulation and Multi-Pathway Effects Beyond Weight Reduction

Randomized trial in 20 peopleLiraglutide

The Journals of Gerontology, Series AMay 26

Relationships of GDF8 and 11 and Their Antagonists With Decline of Grip Strength Among Older Adults in the Baltimore Longitudinal Study of Aging

Cohort study of 534 peopleMechanisms

ProteomicsMay 17

A targeted proteomic assay for the measurement of plasma proteoforms related to human aging phenotypes

Cross-sectional study of 24 peopleBiomarkers

Molecular and Cellular EndocrinologyDec 22

Effects of oral creatine and resistance training on serum myostatin and GASP-1

Randomized trial in 27 peopleCreatine